Home / Oncology (page 5)

Oncology

Puma Announces Top Line Results of the Phase 3 Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced top line results from the Phase III NALA trial of the Company’s lead drug candidate PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease) in the …

Read More »

Bristol-Myers Squibb and H3 Biomedicine Collaborate to Advance Novel Therapeutics Leveraging H3’s RNA Splicing Platform

NEW YORK, TOKYO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and its U.S.-based precision medicine research & development subsidiary H3 Biomedicine, Inc. (Massachusetts, “H3”) today announced a multi-year research collaboration focused on evaluating whether novel therapeutics leveraging H3’s RNA splicing platform can …

Read More »

Celltrion and Teva Announce FDA Approval of Herzuma, a Biosimilar to Herceptin, for Treatment of HER2-Overexpressing Breast Cancer

INCHEON, South Korea & JERUSALEM–(BUSINESS WIRE)–Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved HERZUMA® (trastuzumab-pkrb), a HER2/neu receptor antagonist biosimilar to HERCEPTIN®1 (trastuzumab) for the following indications: Adjuvant Breast Cancer of HER2 overexpressing node positive or node negative (ER/PR …

Read More »

Vargatef Plus Docetaxel Could be an Option After Failure of Immunotherapy in Lung Cancer

INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study …

Read More »

Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer

GENEVA, Dec. 14, 2018 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported safety and promising activity of BPX-601 in Part 1 of a Phase 1/2 dose-escalation study in patients with advanced, metastatic pancreatic cancer expressing PSCA (prostate stem …

Read More »

Guardant Health Partners with AstraZeneca to Develop Blood-Based Companion Diagnostic Tests for Tagrisso and Imfinzi

REDWOOD CITY, Calif., Dec. 13, 2018 (GLOBE NEWSWIRE) — Guardant Health (Nasdaq: GH) announced a multi-year agreement with AstraZeneca (NYSE: AZN) to develop blood-based companion diagnostic (CDx) tests supporting the commercialization of AstraZeneca’s oncology portfolio based on Guardant’s industry-leading comprehensive liquid biopsy platform. Under the terms of the agreement, Guardant …

Read More »

Dragonfly Therapeutics Announces Celgene In-license of First Two TriNKET Immunotherapy Drug Candidates

WALTHAM, Mass., Dec. 13, 2018 /PRNewswire/ — Dragonfly Therapeutics, Inc. (“Dragonfly” or the “Company”), today announced it has licensed two TriNKET™ immunotherapy drug candidates to Celgene Corporation and its affiliates (“Celgene”) for $12m each plus prospective milestones and royalties.  The licenses represent the first two of four hematological cancer targets …

Read More »

OncoSec Reports Updated Tumor Responses in Phase 2b Study of Tavo in Combination with Keytruda in Refractory Metastatic Melanoma

SAN DIEGO and PENNINGTON, N.J, Dec. 12, 2018 /PRNewswire/ — OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing novel cancer immunotherapies, today announced an update regarding tumor responses in its KEYNOTE-695 global, multicenter Phase 2b, open-label trial of intratumoral delivery of TAVO™ (tavokinogene telseplasmid / IL-12) with intravenous KEYTRUDA® …

Read More »

Daiichi Sankyo and Sarah Cannon Research Institute Launch Strategic Collaboration to Develop Novel Cancer Therapies

NASHVILLE, Tenn. and TOKYO and MUNICH and BASKING RIDGE, N.J., Dec. 10, 2018 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute announced today a strategic oncology development collaboration. This partnership brings together Daiichi Sankyo’s expertise in developing novel cancer agents with Sarah Cannon’s leadership …

Read More »

FDA Grants Orphan Drug Designation to Merck KGaA’s Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

DARMSTADT, Germany, December 10, 2018 /PRNewswire/ — FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer First regulatory designation for M7824 following recent presentation of first clinical data in BTC BTC is a group of rare, aggressive gastrointestinal cancers associated with limited treatment options and …

Read More »